Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Advanced Triple-Negative Breast Cancer — Systemic Therapy

First-line Second-line SECOND-LINE Advanced TNBC by PD-L1, gBRCA, HER2 status PD-L1+ (CPS ≥10) gBRCA1/2 PD-L1 negative HER2-low (IHC 1–2+) TROP2 (any HER2) First-line Pembrolizumab + chemo KEYNOTE-355 ↗ Targeted PARP inhibitor (ola / tala) OlympiAD ↗ First-line Single-agent chemotherapy no IO benefit ADC Trastuzumab deruxtecan DESTINY-Breast04 ↗ ADC Sacituzumab govitecan ASCENT ↗